SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:15351541.
  • 2
    Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 280:20772082.
  • 3
    Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR 2000 Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Metab 85:41184124.
  • 4
    Pols HA, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ, Qin-sheng G, Galich AM, Vandormael K, Yates AJ, Stych B 1999 Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 9:461468.
  • 5
    Karpf DB, Shapiro DR, Seeman E, Ensrud KE, Johnston CC, Adami S, Harris ST, Santora AC, Hirsch LJ, Oppenheimer L, Thompson D 1997 Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA 277:11591164.
  • 6
    Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:13441352.
  • 7
    Reginster JY, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:8391.
  • 8
    McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster J-Y 2001 Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333340.
  • 9
    Frijlink WB, te Velde J, Bijvoet OLM, Heynen G 1979 Treatment of Paget's disease of bone with 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD). Lancet 1:799803.
  • 10
    Van Breukelen FJM, Bijvoet OLM, van Oosterom AT 1979 Inhibition of osteolytic bone lesions by 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD). Lancet 1:803805.
  • 11
    Bijvoet OLM, Frijlink WB, Jie K, van de Linden H, Meijer CJLM, Mulder H, van Paassen HC, Reitsma PH, te Velde J, de Vries E, vd Wey JP 1980 APD in Paget's disease of bone, role of the mononuclear phagocyte system? Arthritis Rheum 23:11931204.
  • 12
    Hoekman K, Papapoulos SE, Peters ACB, Bijvoet OLM 1985 Characteristics of bisphosphonate treatment of a patient with juvenile osteoporosis. J Clin Endocrinol Metab 61:952956.
  • 13
    Reid IR, King AR, Alexander CJ, Ibbertson HK 1988 Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet 1:143146.
  • 14
    Valkema R, Vismans F-JFE, Papapoulos SE, Pauwels EKJ, Bijvoet OLM 1989 Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner 5:183192.
  • 15
    Fromm GA, Vega E, Plantalech L, Galich AM, Mautalen CA 1991 Differential action of pamidronate on trabecular and cortical bone in women with involutional osteoporosis. Osteoporos Int 1:129133.
  • 16
    Thiebaud D, Burckhardt P, Melchior J, Eckert P, Jacquet AF, Schnyder P, Goebelt C 1994 Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. Osteoporos Int 4:7683.
  • 17
    Reid IR, Wattie DJ, Evans MC, Gamble GD, Stapleton JP, Cornish J 1994 Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. J Clin Endocrinol Metab 79:15951599.
  • 18
    Lees B, Garland SW, Walton C, Ross D, Whitehead MI, Stevenson JC 1996 Role of oral pamidronate in preventing bone loss in postmenopausal women. Osteoporos Int 6:480485.
  • 19
    Ryan PJ, Blake GM, Davie M, Haddaway M, Gibson T, Fogelman I 2000 Intermittent oral disodium pamidronate in established osteoporosis: A 2-year double-masked placebo-controlled study of efficacy and safety. Osteoporos Int 11:171176.
  • 20
    Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP 2001 Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: A prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res 16:104112.
  • 21
    Papapoulos SE, Landman JO, Bijvoet OLM, Löwik CWGM, Valkema R, Pauwels EKJ, Vermeij P 1992 The use of bisphosphonates in the treatment of osteoporosis. Bone 13:S41S49.
  • 22
    Tonino RP, Meunier PJ, Emkey R, Rodriguez-Portales JA, Menkes CJ, Wasnich RD, Bone HG, Santora AC, Wu M, Desai R, Ross PD 2000 Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 85:31093115.
  • 23
    McCloskey EV, Spector TD, Eyres KS, Fern ED, O'Rourke N, Vasikaran S, Kanis JA 1993 The assessment of vertebral deformity: A method for use in population studies and clinical trials. Osteoporos Int 3:138147.
  • 24
    Bravenboer N, Papapoulos SE, Holzmann P, Hamdy NAT, Netelenbos JC, Lips P 1999 Bone histomorphometric evaluation of pamidronate treatment in clinically manifest osteoporosis. Osteoporos Int 9:489493.
  • 25
    Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste-Marie LG, Tenenhouse A, Chines AA 1997 Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337:382387.
  • 26
    Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG 1998 Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339:292299.
  • 27
    Eastell R, Devogelaer JP, Peel NF, Chines AA, Bax DE, Sacco-Gibson N, Nagant de Deuxchaisnes C, Russell RGG 2000 Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int 11:331337.
  • 28
    Reid DM, Hughes RA, Laan RFJM, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP 2000 Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial. J Bone Miner Res 15:10061013.
  • 29
    Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A 2000 Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604610.
  • 30
    Delmas PP, Confavreux E, Genolet G, Garnero P, Gibelin B, Folens C, Yates J Can alendronate be taken before lunch or dinner? A randomized trial in osteoporotic women. Osteoporos Int 11(Suppl 2):S208.
  • 31
    van Beek E, Hoekstra M, van de Ruit M, Lowik C, Papapoulos S 1994 Structural requirements for bisphosphonate actions in vitro. J Bone Miner Res 9:18751882.
  • 32
    Storm T, Thamsborg G, Steiniche T, Genant HK, Sørensen OH 1990 Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:12651271.
  • 33
    Watts HB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC, Yanover MJ, Mysiw WJ, Kohse L, Rao MB, Steiger P, Richmond B, Chesnut CH 1990 Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:7379.
  • 34
    Reginster JY, Christiansen C, Roux C, Fechtenbaum J, Rouillon A, Tou KP 2001 Intermittent cyclical administration of tiludronate in the treatment of osteoporosis. Osteoporos Int 12:169172.
  • 35
    McCloskey EV, Selby P, Davie M 2000 Oral clodronate significantly reduces fracture risk in women with postmenopausal or secondary osteoporosis. J Bone Miner Res 15(Suppl 1):S227.
  • 36
    Guyatt GH, Sackett DL, Cook DJ 1993 User's guide to medical literature. A. Are the results valid? JAMA 270:25982601.
  • 37
    Papapoulos SE 1996 Bisphosphonates: Pharmacology and use in the treatment of osteoporosis. In: MarcusR, FeldmanD, KelseyJ (eds.) Osteoporosis. Academic Press, San Diego, CA, USA, pp. 12091234.
  • 38
    Meunier PJ, Boivin GI 1997 Bone mineral density reflects bone mass but also the degree of mineralisation of bone: Therapeutic implications. Bone 21:373377.
  • 39
    Boivin GI, Chavassieux PM, Santora AC, Yates J, Meunier PJ 2000 Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27:687694.
  • 40
    Eggelmeijer F, Papapoulos SE, van Paassen HC, Dijkmans BA, Valkema R, Westedt ML, Landman JO, Pauwels EK, Breedveld FC 1996 Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. Arthritis Rheum 39:396402.
  • 41
    Van Holten-Verzantvoort AT, Hermans J, Beex LV, Blijham G, Cleton FJ, van Eck-Smit BC, Sleeboom HP, Papapoulos SE 1996 Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients? Eur J Cancer 32A:450454.
  • 42
    Harinck HIJ, Papapoulos SE, Blanksma HJ, Moolenaar AJ, Vermeij P, Bijvoet OLM 1987 Paget's disease of bone: Early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). BMJ 295:13011305.
  • 43
    Lufkin EG, Argueta R, Whitaker MD, Cameron AL, Wong VH, Egan KS, O'Fallon WM, Riggs BL 1994 Pamidronate: An unrecognized problem in gastrointestinal tolerability. Osteoporos Int 4:320322.